 Methods: a The investigators plan to recruit 100 patients diagnosed with schizophrenia and 100 healthy controls as participants. b At the baseline and Week 12, patient blood samples will be obtained to measure the levels of neuroendocrine substrates and metabolite markers. Clinical symptoms and cognitive function will be evaluated. c For the healthy control participants, blood samples will be obtained once to measure neuroendocrine and metabolite marker levels. 